Evidence map›Paper›PMID 38504771›Full record

ArticleAngewandte Chemie (Weinheim an der Bergstrasse, Germany)2022

Sterically Demanding Flexible Phosphoric Acids for Constructing Efficient and Multi-Purpose Asymmetric Organocatalysts.

Fabian Scharinger, Ádám Márk Pálvölgyi, Melanie Weisz, Matthias Weil, Christian Stanetty, Michael Schnürch, Katharina Bica-Schröder

Abstract read
In one paragraph

Article in Angewandte Chemie (Weinheim an der Bergstrasse, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fabian ScharingerInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0001-8690-3785
Ádám Márk PálvölgyiInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0001-8138-0831
Melanie WeiszInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.
Matthias WeilInstitute of Chemical Technologies and Analytics, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0001-5235-9910
Christian StanettyInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0001-7692-6932
Michael SchnürchInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0003-2946-9294
Katharina Bica-SchröderInstitute of Applied Synthetic Chemistry, TU Wien Getreidemarkt 9/163 1060 Wien Austria.ORCID 0000-0002-2515-9873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we present a novel approach for various asymmetric transformations of cyclic enones. The combination of readily accessible chiral diamines and sterically demanding flexible phosphoric acids resulted in a simple and highly tunable catalyst framework. The careful optimization of the catalyst components led to the identification of a particularly powerful and multi-purpose organocatalyst, which was successfully applied for asymmetric epoxidations, aziridinations, aza-Michael-initiated cyclizations, as well as for a novel Robinson-like Michael-initiated ring closure/aldol cyclization. High catalytic activities and excellent stereocontrol was observed for all four reaction types, indicating the excellent versatility of our catalytic system. Furthermore, a simple change in the diamine's configuration provided easy access to both product antipodes in all cases.

Indexed as

Asymmetric CatalysisAziridinationCyclizationEpoxidationPhosphoric Acids

Identifiers

PMID38504771
PMCPMC10947075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.